Paratek Pharmaceuticals

This Thanksgiving, we’re incredibly grateful for the Paratek team’s dedication and commitment to giving back to the community. Last week, we had the privilege of serving Thanksgiving lunch to guests at the Norristown Hospitality Center—a reminder of the importance of community and compassion. We’re truly thankful for all you do. #Thankful #ParatekProud

According to the CDC, Clostridioides difficile (C. diff) is a serious healthcare-associated infection, affecting nearly 500,000 people annually in the U.S., yet most Americans remain unaware of this infectious disease.  November is C. diff Awareness Month—learn about the symptoms, risk factors, and crucial prevention tips, including the importance of responsible antibiotic use. Discover more from the National Foundation for Infectious Diseases (NFID): https://bit.ly/4hTrGCK  

Antibiotic resistance poses a growing threat, and Antibiotics Awareness Week reminds us to prioritize responsible antibiotic use to combat antibiotic resistance. Misuse today can mean fewer treatment options tomorrow. Healthcare providers, patients, and communities must work together to safeguard these essential medicines for the future. #USAAW24 #AntimicrobialResistance 

Congratulations to the winners of the 2024 Vivli AMR Surveillance Data Challenge! This challenge plays a critical role in advancing our understanding of antimicrobial resistance (AMR), a global health threat that demands innovation, collaboration, and actionable insights. By leveraging cutting-edge data, these winners are paving the way for new strategies to tackle AMR, ultimately helping to protect patient health worldwide. Paratek is proud to support this important initiative and to stand alongside leaders dedicated to combatting AMR. Together, we’re fostering a future where data-driven solutions bring us closer to overcoming one of healthcare’s biggest challenges. 

We’re proud to partner with Biomedical Advanced Research and Development Authority (BARDA) to help enhance national preparedness and response to public health threats through the onshoring of NUZYRA® (omadacycline) manufacturing. This milestone strengthens the U.S. supply of critical medications, supporting resilient healthcare infrastructure and public health.  

Paratek Pharmaceuticals has achieved a major milestone! NUZYRA® (omadacycline) now has fully domestic U.S. manufacturing and supply capabilities, reinforcing our commitment to helping enhance national preparedness and response to public health threats. This achievement is part of our partnership with BARDA, helping to ensure a secure, reliable supply of this important medication. Learn more about this news and our continued work to address critical health needs. https://bit.ly/4fMgbLs

We recognize the incredible contributions of over 385,000 Nurse Practitioners and the essential care they provide to patients every day.  Want to learn more about the impact NPs have on healthcare? Visit the American Association of Nurse Practitioners website here: https://bit.ly/3UR3qHP  #NPWeek  

On World Pneumonia Day, we recognize the global impact of pneumonia and the urgent need to tackle antimicrobial resistance (AMR). Pneumonia is a major health threat, and AMR only heightens its risk. Learn how the Every Breath Counts Coalition is working to reduce the toll of this preventable disease and explore how you can make a difference: https://bit.ly/475OfhR  

Biotech News: Paratek Pharmaceuticals announces positive Top-Line Data from Phase 2b Study in Nontuberculous Mycobacterial (NTM) Abscessus Pulmonary Disease. Read the release: https://bit.ly/3Ce6Opu In a first-of-its-kind Phase 2b study, Paratek's omadacycline showed promising results in patients with Mycobacterium abscessus complex (MABc) pulmonary disease, a serious condition with limited treatment options. Today's news explores how the study demonstrated measurable improvements in symptom severity, quality of life, and negative sputum cultures. 

At Paratek, our people are the cornerstone of our success, and Renee Pohle, Senior Manager of Accounting, definitely brings this to life. Since joining in November 2022, Renee has played a vital role in our finance team, managing key financial processes like quarterly and annual reporting and overseeing our financial auditors. Through the complexities of transitioning from a public to a private company, Renee’s leadership and attention to detail helped us seamlessly navigate these changes, ensuring that our financial statements remained accurate and met our new reporting needs. What truly sets Renee apart is her passion for making a difference. After graduating from the Peter T. Paul College of Business and Economics at the University of New Hampshire with a degree in Science in Business Administration, Accounting and Finance, she started her career auditing real estate companies before she pivoted to the biotech and pharmaceutical world. There she found deeper meaning in her work, knowing her efforts contribute to life-saving therapies. We’re proud to have Renee as part of the Paratek family, where she continues to drive success and inspire those around her! #ParatekProud